Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Carisma Therapeutics ( (CARM) ) is now available.
Carisma Therapeutics Inc. announced plans to wind down its operations, including the termination of key executives. On October 15, 2025, the company notified CEO Steven Kelly and Chief Scientific Officer Michael Klichinsky of their employment termination without cause, effective November 15, 2025, and October 15, 2025, respectively. The company has entered into separation agreements with both executives, detailing their severance packages. Additionally, several board members, including Kelly, have resigned, effective October 15, 2025, as part of the company’s orderly wind-down process.
The most recent analyst rating on (CARM) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Carisma Therapeutics stock, see the CARM Stock Forecast page.
Spark’s Take on CARM Stock
According to Spark, TipRanks’ AI Analyst, CARM is a Neutral.
Carisma Therapeutics’ overall stock score is primarily impacted by its poor financial performance and weak valuation. The company’s financial instability, negative equity, and liquidity issues are significant concerns. Technical analysis suggests a bearish trend, with some potential for stabilization. The lack of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on CARM stock, click here.
More about Carisma Therapeutics
Average Trading Volume: 8,994,443
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.91M
Find detailed analytics on CARM stock on TipRanks’ Stock Analysis page.